July 25, 2021
Video
The chief medical officer of Scholar Rock discussed the upcoming phase 3 trial for apitegromab in SMA and whether a successful trial would warrant FDA submission.
July 20, 2021
Video
The chief medical officer of Scholar Rock discussed the greatest areas of concern for patients with SMA and why most of these issues exist in the diagnostic stage.
July 12, 2021
Video
The chief medical officer of Scholar Rock detailed the additive benefits apitegromab has in treating SMA when used with previously approved nusinersen.
July 05, 2021
Video
The chief medical officer of Scholar Rock discussed topline results from the phase 2 TOPAZ study of apitegromab in patients with spinal muscular atrophy.
Serum Neurofilament Light Poses as Critical Biomarker During Ataxic, Preataxic Stages of Spinocerebellar Ataxias
Connecting ALS: How New Drug Coverage Decisions Are Made
NeuroVoices: Mark Lew, MD, on the Validation of Tears as a Biomarker for Parkinson Disease
AlzoSure Predict Test Shows Predictive Ability for Alzheimer Disease Years Prior to Diagnosis